{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:59:56Z","timestamp":1793289596203,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","clinicalnutritionespen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition ESPEN"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.clnesp.2024.12.005","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T16:52:42Z","timestamp":1734108762000},"page":"357-364","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["An open-label, randomized, controlled trial on the benefit of \u03b2-hydroxy-\u03b2-methyl butyrate, l-arginine, l-glutamine combination beverages and locomotion training as supportive care for the treatment of unresectable hepatocellular carcinoma using lenvatinib: A pilot study (HELLO study)"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0663-0102","authenticated-orcid":false,"given":"Atsushi","family":"Naganuma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujio","family":"Makita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Sakamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Kouno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Ario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yatsuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clnesp.2024.12.005_bib1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamaoncol.2023.2677","article-title":"Critical appraisal of guideline recommendations on systemic therapies for advanced hepatocellular carcinoma: a review","volume":"10","author":"Cappuyns","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clnesp.2024.12.005_bib2","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clnesp.2024.12.005_bib3","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.clnesp.2024.12.005_bib4","first-page":"291","article-title":"Association between skeletal muscle depletion and sorafenib treatment in male patients with hepatocellular carcinoma: a retrospective cohort study","volume":"71","author":"Naganuma","year":"2017","journal-title":"Acta Med Okayama"},{"key":"10.1016\/j.clnesp.2024.12.005_bib5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000504604","article-title":"Skeletal muscle mass influences tolerability and prognosis in hepatocellular carcinoma patients treated with lenvatinib","volume":"9","author":"Uojima","year":"2020","journal-title":"Liver Cancer"},{"key":"10.1016\/j.clnesp.2024.12.005_bib6","doi-asserted-by":"crossref","first-page":"R701","DOI":"10.1152\/ajpregu.00840.2010","article-title":"\u03b2-Hydroxy-\u03b2-methylbutyrate reduces myonuclear apoptosis during recovery from hind limb suspension-induced muscle fiber atrophy in aged rats","volume":"301","author":"Hao","year":"2011","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.clnesp.2024.12.005_bib7","doi-asserted-by":"crossref","first-page":"E91","DOI":"10.1152\/ajpendo.00500.2013","article-title":"Protein synthesis in skeletal muscle of neonatal pigs is enhanced by administration of \u03b2-hydroxy-\u03b2-methylbutyrate","volume":"306","author":"Wheatley","year":"2014","journal-title":"Am J Physiol Endocrinol Metabol"},{"key":"10.1016\/j.clnesp.2024.12.005_bib8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2478\/hukin-2019-0070","article-title":"Mechanism of action and the effect of beta-hydroxy-beta-methylbutyrate (HMB) supplementation on different types of physical performance - a systematic review","volume":"68","author":"Kaczka","year":"2019","journal-title":"J\u00a0Hum Kinet"},{"key":"10.1016\/j.clnesp.2024.12.005_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117520","article-title":"\u03b2-Hydroxy-\u03b2-methylbutyrate (HMB) normalizes dexamethasone-induced autophagy-lysosomal pathway in skeletal muscle","volume":"10","author":"Gir\u00f3n","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clnesp.2024.12.005_bib10","first-page":"155","article-title":"Beta-hydroxy-beta-methyl butyrate\/L-arginine\/L-glutamine supplementation for preventing hand-foot skin reaction in sorafenib for advanced hepatocellular carcinoma","volume":"33","author":"Naganuma","year":"2019","journal-title":"In\u00a0vivo (Athens, Greece)"},{"key":"10.1016\/j.clnesp.2024.12.005_bib11","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/ageing\/afu115","article-title":"Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS)","volume":"43","author":"Cruz-Jentoft","year":"2014","journal-title":"Age Ageing"},{"key":"10.1016\/j.clnesp.2024.12.005_bib13","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.clnesp.2024.12.005_bib14","series-title":"JUVEN\u00ae Therapeutic nutrition drink mix with a unique blend of key ingredients to support wound healing","year":"2019"},{"key":"10.1016\/j.clnesp.2024.12.005_bib15","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/SPC.0b013e328331124a","article-title":"The emerging role of computerized tomography in assessing cancer cachexia","volume":"3","author":"Prado","year":"2009","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.clnesp.2024.12.005_bib16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.clnesp.2024.12.005_bib17","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1524-4733.2008.00449.x","article-title":"Assessing items on the SF-8 Japanese version for health-related quality of life: a psychometric analysis based on the nominal categories model of item response theory","volume":"12","author":"Tokuda","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.clnesp.2024.12.005_bib18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00535-019-01642-1","article-title":"REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset","volume":"55","author":"Yamashita","year":"2020","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.clnesp.2024.12.005_bib19","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/hepr.13460","article-title":"Analyses of objective response rate, progression-free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: a multicenter retrospective study","volume":"50","author":"Hatanaka","year":"2020","journal-title":"Hepatol Res : Off J Jap Soci Hepatol"},{"key":"10.1016\/j.clnesp.2024.12.005_bib20","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41598-022-27238-z","article-title":"Association between sarcopenia and clinical outcomes in patients with hepatocellular carcinoma: an updated meta-analysis","volume":"13","author":"Guo","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.clnesp.2024.12.005_bib21","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/jcsm.12952","article-title":"Effects of \u03b2-hydroxy \u03b2-methylbutyrate (HMB) supplementation on muscle mass, function, and other outcomes in patients with cancer: a systematic review","volume":"13","author":"Prado","year":"2022","journal-title":"J\u00a0Cach Sarcop Mus"},{"key":"10.1016\/j.clnesp.2024.12.005_bib22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/011542650502000152","article-title":"Arginine supplementation and wound healing","volume":"20","author":"Stechmiller","year":"2005","journal-title":"Nutr Clin Pract"},{"key":"10.1016\/j.clnesp.2024.12.005_bib23","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.burns.2004.10.027","article-title":"Clinical and protein metabolic efficacy of glutamine granules-supplemented enteral nutrition in severely burned patients","volume":"31","author":"Peng","year":"2005","journal-title":"Burns"},{"key":"10.1016\/j.clnesp.2024.12.005_bib24","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.clnesp.2023.08.027","article-title":"Efficacy of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine for the prevention of mucositis induced by platinum-based chemoradiation in head and neck cancer: a phase II study","volume":"57","author":"Kuroki","year":"2023","journal-title":"Clin Nutr ESPEN"},{"key":"10.1016\/j.clnesp.2024.12.005_bib25","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/jjco\/hyu027","article-title":"Effect of HMB\/Arg\/Gln on the prevention of radiation dermatitis in head and neck cancer patients treated with concurrent chemoradiotherapy","volume":"44","author":"Imai","year":"2014","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clnesp.2024.12.005_bib26","first-page":"2457","article-title":"Efficacy of AboundTM for hand-foot syndrome caused by capecitabine","volume":"40","author":"Fujii","year":"2013","journal-title":"Gan to kagaku ryoho Cancer & chemotherapy"},{"key":"10.1016\/j.clnesp.2024.12.005_bib27","article-title":"Utilization of hydroxyl-methyl butyrate, leucine, glutamine and arginine supplementation in nutritional management of sarcopenia-implications and clinical considerations for type 2 diabetes mellitus risk modulation","volume":"10","author":"Maykish","year":"2020","journal-title":"J\u00a0Personalized Med"}],"container-title":["Clinical Nutrition ESPEN"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240545772401550X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240545772401550X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T15:47:25Z","timestamp":1737388045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240545772401550X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":26,"alternative-id":["S240545772401550X"],"URL":"https:\/\/doi.org\/10.1016\/j.clnesp.2024.12.005","relation":{},"ISSN":["2405-4577"],"issn-type":[{"value":"2405-4577","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An open-label, randomized, controlled trial on the benefit of \u03b2-hydroxy-\u03b2-methyl butyrate, l-arginine, l-glutamine combination beverages and locomotion training as supportive care for the treatment of unresectable hepatocellular carcinoma using lenvatinib: A pilot study (HELLO study)","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition ESPEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnesp.2024.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}